Celecoxib/Ciprofloxacin

NeuroSense Therapeutics will showcase new data from PrimeC's Phase 2b trial in ALS at the American Academy of Neurology Meeting on April 8, 2025, featuring presentations on clinical outcomes and microRNA biomarker findings.

Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.

NeuroSense Therapeutics has regained compliance with Nasdaq's minimum equity requirement, ensuring its stock remains listed on the Nasdaq Capital Market.

NeuroSense's PrimeC demonstrated significant benefits in ALS treatment during a Phase 2b clinical trial, extending complication-free survival by 53% compared to placebo. The therapy also showed improvements in patients' quality of life, leading to discussions with U.S. regulators about Phase 3 trials and potential early approval in Canada.

NeuroSense Therapeutics has entered a binding term sheet with a leading global pharmaceutical company for PrimeC development, securing upfront payment and Phase 3 trial funding.